The following passage is of significant interest:
'PTX-200 is a novel and selective Akt activation inhibitor. It is both anti-proliferative and pro-apoptotic.
Most Akt inhibitors seek to work by mimicking ATP, a molecule used by all kinases in the cells; and
therefore off target effects are likely to result in toxicities.
By contrast, the mechanism by which PTX-200 inactivates Akt is not by inhibiting its kinase, but rather
by binding to the PH domain of Akt and preventing its binding to the plasma membrane where it must
be localized to be phosphorylated and activated. Therefore, by preventing Akt binding to the plasma
membrane, PTX-200 inhibits Akt, but without the off target toxic effects of kinase inhibitors.
Hyperactive Akt is a prominent feature of many human cancers and is correlated with resistance to
chemotherapy.'
Most interest is usually based on active imformation such as efficacy and or potency of data validating drug performance. Reactive interest, such as toxicity data, is usually the reality check on meta performance...
Ummm, might be another piece to the puzzle as to why the recent additions to the ptx team from such prominent experts, afterall they often have an academic influence of duty of care.
Ofcoures, all in my opinion only, but it may be the case that as holders we are now becoming more aware of the science potential that is attracting this team of experts to unite.
GLTAH
PTX Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
